TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC

NCT05250843 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE: TACE/HAIC
DRUG: Lenvatinib
DRUG: Sintilimab
PROCEDURE: liver resection

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University